Aspirin Prevention of Colorectal Cancer

Citation for published version:
Chen, J & Stark, LA 2017, 'Aspirin Prevention of Colorectal Cancer: Focus on NF-B Signalling and the Nucleolus' Biomedicines, vol 5, no. 3. DOI: 10.3390/biomedicines5030043

Digital Object Identifier (DOI):
10.3390/biomedicines5030043

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published In:
Biomedicines

Publisher Rights Statement:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and/or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Review

Aspirin Prevention of Colorectal Cancer: Focus on NF-κB Signalling and the Nucleolus

Jingyu Chen and Lesley A. Stark *

Cancer Research UK Edinburgh Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Crewe Rd., Edinburgh, Scotland EH4 2XU, UK; s1355550@sms.ed.ac.uk
* Correspondence: Lesley.Stark@IGMM.ed.ac.uk; Tel.: +44-131-651-8531

Received: 20 June 2017; Accepted: 13 July 2017; Published: 18 July 2017

Abstract: Overwhelming evidence indicates that aspirin and related non-steroidal anti-inflammatory drugs (NSAIDs) have anti-tumour activity and the potential to prevent cancer, particularly colorectal cancer. However, the mechanisms underlying this effect remain hypothetical. Dysregulation of the nuclear factor-kappaB (NF-κB) transcription factor is a common event in many cancer types which contributes to tumour initiation and progression by driving expression of pro-proliferative/anti-apoptotic genes. In this review, we will focus on the current knowledge regarding NSAID effects on the NF-κB signalling pathway in pre-cancerous and cancerous lesions, and the evidence that these effects contribute to the anti-tumour activity of the agents. The nuclear organelle, the nucleolus, is emerging as a central regulator of transcription factor activity and cell growth and death. Nucleolar function is dysregulated in the majority of cancers which promotes cancer growth through direct and indirect mechanisms. Hence, this organelle is emerging as a promising target for novel therapeutic agents. Here, we will also discuss evidence for crosstalk between the NF-κB pathway and nucleoli, the role that this cross-talk has in the anti-tumour effects of NSAIDs and ways forward to exploit this crosstalk for therapeutic purpose.

Keywords: Aspirin; non-steroidal anti-inflammatory drugs; nuclear factor kappaB; apoptosis; colon cancer; nucleolus; nucleolar; nucleoli; sequestration; stress; RelA; p65

1. Aspirin and Cancer

Incontrovertible evidence from laboratory, clinical and epidemiological studies indicates that aspirin and related non-steroidal anti-inflammatory drugs (NSAIDs) have anti-neoplastic properties and considerable potential as chemopreventative/therapeutic agents [1–4]. For example, at therapeutic concentrations, NSAIDs induce cell cycle arrest and atypical apoptosis in cancer cell lines [5–8]. In animal studies, NSAID administration significantly reduces tumour burden in the azoxymethane-induced rat model of colorectal cancer [9]. NSAIDs also reduce tumour burden and increase survival in the multiple intestinal neoplasia (Min/+) model of colorectal cancer [10–12]. However, in this model tumour burden is mostly affected when mice are exposed to NSAIDs in utero, suggesting the agents act at the early stages of tumour development [13,14]. Meta-analysis of randomised clinical trials (RCTs) for the prevention of vascular disease indicate daily aspirin (75 mg upwards) reduces cancer incidence and mortality. These effects are particularly evident for colorectal cancer where a 30% to 40% reduction in incidence and mortality are observed [15,16]. The risk of developing distant metastasis is also reduced in aspirin users, suggesting a potential benefit for patients with established disease [17,18]. RCTs for cancer prevention indicate aspirin limits recurrence of spontaneous and hereditary intestinal adenomas (the precursor lesion to most cancers). After long term followup, they also indicate aspirin prevents colorectal cancer in (1) women randomised to alternate day low dose (75 mg) aspirin; and (2) patients with Lynch syndrome (the most common type of hereditary colon cancer) [4,19–23].
most compelling evidence for the chemopreventative effects of NSAIDs comes from epidemiological studies which have consistently demonstrated reduced cancer incidence and improved survival in persons who regularly take aspirin or other NSAIDs [16,24–26]. Again, this association is particularly strong for colorectal cancer, with other cancer types showing less consistent risk reduction.

The predominant anti-tumour activity of NSAIDs is recognized to be the selective induction of apoptosis in neoplastic cells [10,27]. However, the mechanisms underlying this pro-apoptotic activity are complex, interconnected, and remain controversial [4,28,29]. In 1982, John R Vane was awarded the Nobel Prize for discovering that aspirin irreversibly acetylates the cyclooxygenase enzymes, thereby blocking the conversion of arachidonic acid to prostaglandins [30]. Cyclo-oxygenase-2 (COX-2 (PTGS2)), the inducible form of the enzyme, is frequently upregulated in cancer and together with PGE$_2$, is implicated in several aspects of malignant growth including stem cell proliferation, migration, angiogenesis, apoptosis resistance, invasion, and metastasis [31–34]. Hence, inhibition of COX-2 activity was thought to be the main mechanism for the anti-tumour effects of NSAIDs. Indeed, a body of literature supports this suggestion [35–39]. More recently, it was proposed that aspirin acetylation of COX-1 in platelets, and the consequent inactivation of platelet function, is the only mechanism that can explain the anti-tumour properties of aspirin when taken at low dose [29,40,41]. However, NSAIDs induce cell cycle arrest and apoptosis in colon cancer cell lines that do not express COX-1 or COX-2 enzymes and in mouse embryo fibroblasts that are null for both COX-1 and COX-2 genes [42–44]. The growth inhibitory properties of NSAIDs cannot be reversed by addition of prostaglandins [4,9]. Furthermore, NSAID metabolites that do not appreciably affect the catalytic activity of COXs retain their anti-tumor properties in tissue culture [27] and animal models [45,46]. Hence, there is powerful evidence that inhibition of COX is not the only mechanism by which NSAIDs induce apoptosis and prevent the growth of neoplastic lesions [28,47]. A number of COX-independent targets have been identified including the WNT [10,48], AMPK [49,50] and MTOR [51] signalling pathways (reviewed in [4]). In the rest of this review we will focus on the role of nuclear factor-kappaB (NF-$\kappa$B). In particular, we will examine the evidence for crosstalk between NF-$\kappa$B signalling and nucleoli in the regulation of NF-$\kappa$B transcriptional activity and NSAID-mediated apoptosis.

2. NF-$\kappa$B, Cancer and Aspirin

NF-$\kappa$B is the collective name for a family of ubiquitously expressed, inducible transcription factors that play a critical role in multiple processes including innate and adaptive immune response, inflammation, differentiation, proliferation and survival [52–54]. In mammalian cells there are five family members namely, RelA (p65), RelB, c-Rel, p105/p50 (NF-$\kappa$B1), and p100/p52 (NF-$\kappa$B2) [55]. These proteins homo- and hetero-dimerize through their Rel homology domain to create a variety of transcription factor complexes [56]. The most common form of NF-$\kappa$B is p50/RelA heterodimers. In most cell types, this complex exists in the cytoplasm bound to a family of I$\kappa$B inhibitory proteins (I$\kappa$B$\alpha$, I$\kappa$B$\beta$, I$\kappa$B$\gamma$ and Bcl-3). Following cellular stimulation by a plethora of stimuli including cytokines, pathogens, viruses and stresses, I$\kappa$B proteins are phosphorylated by the I$\kappa$B kinase (IKK) complex then degraded by the 26S proteasome [57]. Subsequently, NF-$\kappa$B translocates to the nucleus where it regulates the transcription of target genes including those involved immune function, inflammation, cell adhesion, differentiation, cell growth, and apoptotic cell death.

In healthy cells, a number of feedback mechanisms ensure that activation of the NF-$\kappa$B pathway is transient [53,56]. However, in chronic inflammatory conditions and cancer, NF-$\kappa$B is aberrantly active which contributes to disease progression by promoting inflammation, blocking differentiation, driving stem cell proliferation and inhibiting apoptosis [53,54,58].

A substantial body of data supports a critical role for dysregulated NF-$\kappa$B activity in intestinal tumorigenesis, the cancer type most responsive to aspirin treatment. For example, a recent meta-analysis of expression studies revealed that high expression of NF-$\kappa$B is significantly associated with late stage colorectal cancer (TNM stage III–IV) and a worse overall 3 and 5-year survival [59]. Transgenic mice with constitutively active IKK in intestinal epithelial cells develop intestinal tumours
and show accelerated adenoma development when crossed to Min/+ mice [60]. Conversely, inactivation of IKK in intestinal epithelial or myeloid cells attenuates inflammation-associated tumour development [61]. Furthermore, deletion of RelA in intestinal epithelial cells prevents formation of adenomas in the Min/+ model [62]. These data have identified inhibition of NF-κB activity as a promising therapeutic target for the treatment of this disease.

Targeting of the NF-κB pathway by NSAIIDs was initially reported by Kopp and Ghosh in 1994, who demonstrated that the aspirin derivative, sodium salicylate, inhibits lipopolysaccharide (LPS) and phorbol 12-myristate 13-acetate (PMA)/phytohemagglutinin (PHA)-mediated degradation of IκB, nuclear translocation of NF-κB and NF-κB transcriptional activity [63]. Yin et al. subsequently demonstrated that salicylate specifically inhibits IKKβ activity in cell lines in vivo and when the agent is added to the kinase in vitro [64]. Since these early publications, NSAID modulation of the NF-κB pathway has been widely reported [28,65]. However, these studies have produced contrasting results dependent upon cell lines and experimental design. In most studies aimed at examining this relationship, cells are treated with NSAIIDs for 1–2 h prior to activation of the NF-κB pathway by a potent stimulus (e.g., LPS, Interleukin-1 (IL-1), tumour necrosis factor (TNF)). Under these conditions, NSAIIDs block activation of the NF-κB pathway and there is some evidence from in vitro and animal studies to suggest that inhibition of IκB degradation is responsible for the anti-tumour effect of the agents [66–68] (Figure 1). However, this experimental design is entirely inconsistent with the protocol used to demonstrate NSAID-mediated apoptosis of cancer cells, where cells are exposed to the agents for prolonged periods in the absence of additional stimuli [5–8].

Examination of aspirin effects on NF-κB signalling using this alternative protocol revealed that prolonged treatment of colorectal cancer cells with pharmacologically relevant doses (0.5–5 mM) of aspirin alone actually stimulates the NF-κB pathway, as evidenced by phosphorylation/degradation of IκB and nuclear translocation of RelA [8] (Figure 1). Furthermore, using cells expressing degradation resistant IκB (super-repressor), Stark et al. demonstrated that this stimulation is absolutely required for the pro-apoptotic effects of the agent [8] (Figure 1). Interestingly, stimulation of the NF-κB pathway by aspirin, and the consequent induction of apoptosis, were particularly evident in colorectal cancer cells, which is in keeping with the increased sensitivity of this cancer type to the chemopreventative effects of the agent [7,8]. The NSAIIDs diclofenac, sulindac, sulindac sulphone sulindac sulphide, Tolfenamic, indomethacin, celecoxib and ibuprofen, which are all known to protect against colorectal cancer, have also been shown to induce degradation of IκB and nuclear translocation of NF-κB in various cancer cell lines in the absence of additional NF-κB stimuli [69–75]. Furthermore, in the majority of these studies, NSAIID-mediated activation of the NF-κB pathway was causally associated with the induction of apoptosis.

As the above data were generated using tissue culture systems, it was argued that the conditions are not representative of the tumour environment where inflammatory cytokines are abundant. To address this concern, our group examined the effects of aspirin on NF-κB signalling in colorectal neoplasia in vivo, using the HT-29 xenograft and Min/+ mouse models. We found that aspirin (at doses resulting in serum salicylate levels relevant to humans (0.5–1.5 mM)) induces phosphorylation and degradation of IκBα, nuclear translocation of RelA and the induction of apoptosis in xenografted HT-29 tumours and in adenomas from Min/+ mice [76]. Sulindac sulphide has also been shown to induce degradation of IκB and nuclear translocation of NF-κB in the proximal colons of mice [72]. Furthermore, exposure to low dose (100 µM) aspirin ex vivo was recently shown to stimulate the NF-κB pathway, as evidenced by increased phosphorylation of RelA at serine 536, in 5 of 6 freshly resected, human colorectal tumours [77]. These findings establish that aspirin and other NSAIIDs activate the NF-κB pathway in neoplastic epithelial cells in the context of a whole tumour setting, and support the proposition that this effect is important for the anti-tumour activity of the agent.

In reality, NSAIIDs likely both activate and suppress activation of the NF-κB pathway in cancer depending on the tumour type and microenvironment. Most solid malignancies require an intrinsic inflammatory response to promote a pro-tumorigenic microenvironment [78]. NSAIIDs are thought
to act against pre-malignant lesions, at least in part, by altering this response. That is, suppressing pro-tumorigenic immune cell populations while stimulating the adaptive immune system [79]. Notably, colorectal cancer response to NSAIDs is associated with a reduced number of tumour infiltrating lymphocytes [80]. Therefore, it is interesting to speculate that by blocking stimulation of the NF-κB pathway, NSAIDs modulate the tumour microenvironment to reduce the presence of inflammatory cells/cytokines, while stimulation of the pathway in a non-inflammatory environment mediates apoptosis of colorectal cancer cells.

**Figure 1.** Aspirin modulation of the nuclear factor-kappaB (NF-κB) pathway. (Left) The NF-κB transcription factor, most commonly a hetero-dimer of the RelA (p65) and p50 polypeptides, is held in the cytoplasm by the inhibitory protein IκB. When the cell is stimulated by growth factors or cytokines (e.g., interleukin-1 (IL-1) or tumour necrosis factor (TNF)), IκB is phosphorylated by the IκB kinase (IKK) complex, which targets it for degradation by the proteasome. This allows NF-κB to translocate to the nucleus and regulate expression of target genes. In cancer cells, NF-κB is constitutively active which drives tumour progression. Short pre-treatment with aspirin or related non-steroidal anti-inflammatory drugs (NSAIDs) blocks cytokine-mediated activation of the pathway by inhibiting the IKK complex, particularly IKKβ; T bar: NSAIDs inhibit IKK kinase activity. IL-1R: IL-1 receptor; TNFR: TNF receptor; NEMO (IKKγ); (Right) In contrast, prolonged exposure to NSAIDs in the absence of additional NF-κB activators stimulates degradation of IκB and nuclear translocation of NF-κB. This NF-κB recruits specific complexes which lead to repression of NF-κB-driven transcription and the induction of apoptosis. Dotted lines: It remains unclear whether the IKK complex plays a role in the stimulatory pathway or whether NSAIDs target IκB by another pathway.
3. Crosstalk between the NF-κB Pathway and Nucleoli

As outlined above, several lines of data indicate that NSAIDs stimulate the NF-κB pathway in vitro and in vivo and that this is important for the anti-tumour activity of the agents. However, in most cases, stimulation of the NF-κB pathway by NSAIDs is associated with repression of NF-κB transcriptional activity and downregulation of NF-κB target genes [65,71,75] (Figure 1). In studies aimed at understanding the mechanisms responsible for this repression, a role for crosstalk between NF-κB signalling and the nuclear organelle, the nucleolus, has emerged.

The nucleolus is a highly dynamic, multifunctional organelle [81–84]. Its main role is in ribosomal biogenesis which is the most energy consuming process in the cell and as such, is tightly linked to metabolic and proliferative activity. If cells are exposed to stresses or insults that threaten homeostasis (e.g., Ultraviolet-C (UV-C) radiation, nutrient deprivation, toxic agents), they respond by rapidly downregulating rDNA transcription. This triggers a cascade of nucleolar events that will either allow the cell to repair and regain homeostasis, or, if the damage is too great, undergo apoptosis. Over half of the 4500 proteins found within nucleoli are involved in processes out with ribosome biogenesis e.g., transcription, cell cycle regulation, ubiquitin modification, proliferation and apoptosis [85,86]. These regulatory proteins flux dynamically between this and other cellular compartments depending upon cellular environment [85,87]. While some are released from nucleoli under conditions of cell stress, others translocate to the organelle. For example, NF-κB repressing factor has recently been shown to accumulate in nucleoli in response to heat stress, causing repression of rDNA transcription [88]. P53 and a variety of ubiquitinated proteins accumulate in nucleoli in response to proteasome inhibition, while exposure of cells to heat shock, hypoxia and acidosis causes the accumulation of proteins with a specific nucleolar retention sequence (i.e., von Hippel-Lindau, DNA methyltransferase 1 (DNMT1) and the DNA polymerase subunit POLD1) in nucleolar foci [89–93]. Indeed, nucleolar sequestration of transcription factors and regulatory proteins is increasingly recognised as an important mechanism for controlling gene expression and maintaining cellular homeostasis under stress conditions.

Many proteins known to shuttle through nucleoli are regulators of the NF-κB pathway. For example, the nucleolar protein p14ARF, which sequesters MDM2 in the nucleolus to regulate p53 stability, interacts with RelA and inhibits NF-κB-driven transcription [94]. In screens for NF-κB-interacting partners, the predominant proteins identified were the nucleolar proteins NFBP [95] and NPM [96]. The NF-κB regulators NIK (NF-κB-inducing kinase) [97] and NRF (NF-κB repressing factor) [98] also function through nucleolar shuttling. Disruption of nucleolar function is a common denominator for stresses that activate the NF-κB pathway [77]. Furthermore, proteins that have a role in stress-mediated activation of NF-κB reside within this organelle, such as CK2, which forms part of the PolI complex and phosphorylates IκB in response to UV-C [99,100] and EIF2α, that plays a role in NF-κB activation in response to multiple stresses [101,102].

When exploring repression of NF-κB-driven transcription associated with stimulation of the NF-κB pathway, it was found that in response to specific pro-apoptotic stress stimuli (e.g., aspirin, serum deprivation and UV-C radiation), the RelA component of NF-κB is sequestered in the nucleolus [65]. A nucleolar localization signal (NoLS) was identified at the N terminus of RelA and, using a dominant-negative mutant with a deletion of this motif, it was shown that nucleolar sequestration of RelA is causally involved in reduced basal NF-κB transcriptional activity and the induction of apoptosis [65] (Figure 2). Importantly, it was found that nucleolar translocation of RelA was absolutely required for the pro-apoptotic activity of aspirin [65,103]. Since this initial study, nucleolar localisation of RelA has been observed in response to the NSAIDs sulindac, sulindac sulphone and indomethacin [71], the naturally occurring derivative of estradiol and antitumor agent, 2-methoxyestradiol (2ME2) [104]; a potent Trk inhibitor and anti-tumour agent, K252a [105]; expression of the homeobox protein Hox-A5 (HOXA5) transcription factor [106], small molecule inhibitors of the CDK4 kinase [107] and the proteasome inhibitors MG132 and lactocystin [103]. In the majority of these studies, nucleolar sequestration of RelA is associated with a decrease in NF-κB-driven transcription. Furthermore, in all studies, it is associated with, or causally involved in, the induction of apoptosis.
Nucleolar sequestration of p50 has also been reported. Park et al. demonstrated that the anti-TNF therapy, infliximab, induces “massive” nucleolar localisation of NF-κB/p50 in the hippocampus of rats with a portacaval shunt (PCS). They also demonstrated that this nucleolar localisation is associated with a decrease in transcription of NF-κB target genes and a reduction in neuroinflammation [108].

Figure 2. NF-κB-nucleolar crosstalk. Upon exposure of cells to specific pro-apoptotic stimuli, including NSAIDs and chemotherapeutic agents, IκB is degraded and RelA/NF-κB translocates to the nucleus. This induced NF-κB/RelA recruits specific co-factors (CF)/modifiers that target both constitutive and induced RelA to the nucleolus, reducing basal NF-κB transcriptional activity [62,101]. Once in the nucleolus, RelA induces the relocation of nucleophosmin (NPM) to the cytoplasm which in turn binds to BAX, then transports BAX to the mitochondria to mediate apoptosis [105]. An early response to stresses that induce nucleolar translocation of RelA is disruption of nucleolar morphology, which may “prime” this organelle for nucleolar residency of RelA. Dashed arrows: pathways still under exploration. Solid arrows: published pathways.

Given that nucleolar sequestration of RelA causes repression of constitutive NF-κB-driven transcription, it was assumed that the apoptotic effects were mediated through a reduction in transcription of NF-κB regulated, anti-apoptotic genes. However, it was found that once in the nucleolus, RelA triggers a cascade of events that actively promotes apoptosis [109] (Figure 2). That is, nucleolar RelA causes nucleophosmin (NPM)/B23 to relocate to the cytoplasm, bind BAX then transport BAX to the mitochondria to initiate apoptosis [110,111]. Indeed this, and a number of other studies have demonstrated a critical role for both BAX and NPM in the pro-apoptotic effects of NSAIDs [112]. Together, these data identify nucleolar-NF-κB crosstalk as an important regulator of NF-κB transcriptional activity and apoptosis and suggest that this is particular critical for the anti-tumour effects of NSAIDs and chemotherapeutic agents.

As mentioned above, aspirin irreversibly acetylates active site serines to inhibit the activity of cyclooxygenase enzymes. However, as an acetylating agent, it has the ability to acetylate other amino acid side chains [113,114]. Tatham et al. (2017) recently used isotopically labelled aspirin-d3, in combination with acetylated lysine purification and LC-MS/MS, to identify over 12,000 sites of aspirin-mediated lysine acetylation in cultured human cells [113]. Interestingly, gene ontology (GO)
analysis indicated that acetylation of nucleolar proteins, including nucleophosmin, was one of the earliest responses to the agent. Immunocytochemical studies also suggest nucleolar morphology is altered as an early response to NSAIDs [65,71], suggesting the intriguing possibility that early effects of these agents on the organelle may enable cross-talk with the NF-κB pathway.

4. Conclusions

Despite the overwhelming proof that aspirin prevents colon and other cancers, these agents are still not recommended for cancer prevention in the general population due to their significant side effect profile. Identification of the precise pathway(s) by which daily aspirin inhibits the initiation/progression of cancer is now paramount so that patient populations who may benefit from exposure to the agent can be identified, and safer, more effective alternatives revealed. Inhibition of the cyclooxygenase enzymes, both in platelets and cancer cells, undoubtedly plays a role. However, given that aspirin acetylates many proteins [113,114], other pathways are more than likely involved. Indeed, multiple lines of evidence suggest the agents act in a COX-dependent and independent manner.

There is a consensus in the literature that NSAIDs induce repression of NF-κB-driven transcription, although the pathway to this repression appears to be cell type and context dependent. Nonetheless, given the critical role of de-regulated NF-κB activity in colorectal cancer initiation and progression, it is extremely likely that this repression contributes significantly to the anti-tumour effect of the agents in humans. There are several lines of cross-talk between the prostaglandin and NF-κB signaling pathways and so, it may be that NSAID inhibition of cyclooxygenases inhibits tumour growth through modulation of the NF-κB pathway. In this regard, Chan et al. suggested that NSAID inhibition of COX activity mediates apoptosis not by reducing prostaglandin levels, but by increasing the generation of ceramide, a potent cytotoxic agent that stimulates the NF-κB pathway to induce cell death [115,116]. As more large scale randomised clinical trials are initiated to examine the anti-tumour and chemopreventative effects of aspirin, it will be possible to definitively establish the effects of aspirin exposure on these signalling pathways in human pre-cancer and cancerous lesions, to understand their individual contributions and to determine how they may be interconnected.

Dysfunction of the nucleolus is now regarded a hallmark of cancer as it contributes to tumour growth not only by allowing the protein synthesis required for rapid cell proliferation, but also through de-regulation of critical nucleolar cell growth and death pathways. Hence, modulation of nucleolar function is emerging as an innovative therapeutic strategy. Recent work has uncovered an exciting new role for the nucleolus in the anti-tumour effects of NSAIDs and in particular, cross-talk between nucleoli and the NF-κB pathway. This evolving field is in its infancy and there are still a number of questions to be answered regarding the role of nucleolar sequestration of RelA in the regulation of NF-κB activity and apoptosis in vivo, and how this contributes to the chemopreventative effect of NSAIDs. Identification of the pathways responsible for nucleolar translocation of RelA would allow development of small molecules that act specifically on cancer cells by targeting chromatin bound RelA to nucleoli. Similarly, identification of the apoptotic pathways triggered by RelA within this organelle would allow the development of RelA mimetics that mediate apoptosis by targeting dysfunctional nucleoli. Indeed, further understanding in this area could reveal a whole new class of targets to be exploited for therapeutic purposes.

**Acknowledgments:** The work was supported by grants from the WWCR (formally AICR 10-0158 to LS), Rosetrees trust (A631 and JS16/M225 to LS) and MRC (MR/J001481/1).

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Tougeron, D.; Sha, D.; Manthravadi, S.; Sinicrope, F.A. Aspirin and colorectal cancer: Back to the future. *Clin. Cancer Res.* **2014**, *20*, 1087–1094. [CrossRef] [PubMed]

2. Patrignani, P.; Patrono, C. Aspirin and Cancer. *J. Am. Coll. Cardiol.* **2016**, *68*, 967–976. [CrossRef] [PubMed]
3. Chan, A.T.; Arber, N.; Burn, J.; Chia, W.K.; Elwood, P.; Hull, M.A.; Logan, R.F.; Rothwell, P.M.; Schrör, K.; Baron, J.A. Aspirin in the chemoprevention of colorectal neoplasia: An overview. Cancer Prev. Res. 2012, 5, 164–178. [CrossRef] [PubMed]

4. Drew, D.A.; Cao, Y.; Chan, A.T. Aspirin and colorectal cancer: The promise of precision chemoprevention. Nat. Rev. Cancer 2016, 16, 173–186. [CrossRef] [PubMed]

5. Elder, D.J.; Hague, A.; Hicks, D.J.; Paraskeva, C. Differential growth inhibition by the aspirin metabolite salicylate in human colorectal tumor cell lines: Enhanced apoptosis in carcinoma and in vitro-transformed adenoma relative to adenoma relative to adenoma cell lines. Cancer Res. 1996, 56, 2273–2276. [PubMed]

6. Williams, C.S.; Smalley, W.; DuBois, R.N. Aspirin use and potential mechanisms for colorectal cancer prevention. J. Clin. Invest. 1997, 100, 1325–1329. [CrossRef] [PubMed]

7. Din, F.V.; Dunlop, M.G.; Stark, L.A. Evidence for colorectal cancer cell specificity of aspirin effects on NF-κB signalling and apoptosis. Br. J. Cancer 2004, 91, 381–388. [PubMed]

8. Stark, L.A.; Din, F.V.; Zwicka, R.M.; Dunlop, M.G. Aspirin-induced activation of the NF-κB signalling pathway: A novel mechanism for aspirin-mediated apoptosis in colon cancer cells. FASEB J. 2001, 15, 1273–1275. [PubMed]

9. Piazza, G.A.; Alberts, D.S.; Hixson, L.J.; Paranka, N.S.; Li, H.; Finn, T.; Bogert, C.; Guillen, J.M.; Brendel, K.; Gross, P.H.; et al. Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res. 1997, 57, 2909–2915. [PubMed]

10. Qiu, W.; Wang, X.; Leibowitz, B.; Liu, H.; Barker, N.; Okada, H.; Oue, N.; Yasui, W.; Clevers, H.; Scheen, R.E.; et al. Chemoprevention by nonsteroidal anti-inflammatory drugs eliminates oncogenic intestinal stem cells via SMAC-dependent apoptosis. Proc. Natl. Acad. Sci. USA 2010, 107, 20027–20032. [CrossRef] [PubMed]

11. Beazer-Barclay, Y.; Levy, D.B.; Moser, A.R.; Dove, W.F.; Hamilton, S.R.; Vogelstein, B.; Kinzler, K.M. Sulindac suppresses tumorigenesis in the Min mouse. Carcinogenesis 1996, 17, 1757–1760. [CrossRef] [PubMed]

12. Corpet, D.E.; Pierre, F. Point: From animal models to prevention of colon cancer. Systematic review of chemoprevention in min mice and choice of the model system. Cancer Epidemiol. Biomark. Prev. 2003, 12, 391–400.

13. Perkins, S.; Clarke, A.R.; Steward, W.; Gescher, A. Age-related difference in susceptibility of ApcMin/+ mice towards the chemopreventive efficacy of dietary aspirin and curcumin. Br. J. Cancer 2003, 88, 1480–1483. [CrossRef] [PubMed]

14. Sansom, O.J.; Stark, L.A.; Dunlop, M.G.; Clarke, A.R. Suppression of intestinal and mammary neoplasia by lifetime administration of aspirin in ApcMin/+ and ApcMin/+; Msh2−/− mice. Cancer Res. 2001, 61, 7060–7064. [PubMed]

15. Rothwell, P.M.; Wilson, M.; Elvin, C.E.; Norrving, B.; Algra, A.; Warlow, C.P.; Meade, T.W. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-Year follow-up of five randomised trials. Lancet 2010, 376, 1741–1750. [CrossRef]

16. Rothwell, P.M.; Price, J.F.; Fowkes, F.G.; Zanchetti, A.; Roncaglioni, M.C.; Tognoni, G.; Lee, R.; Belch, J.F.F. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: Analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 2012, 379, 1602–1612. [CrossRef]

17. Rothwell, P.M.; Wilson, M.; Price, J.F.; Belch, J.F.; Meade, T.W.; Mehta, Z. Effect of daily aspirin on risk of cancer metastasis: A study of incident cancers during randomised controlled trials. Lancet 2012, 379, 1591–1601. [CrossRef]

18. Elwood, P.C.; Morgan, G.; Galante, J.; Chia, J.W.; Dolwani, S.; Graziano, J.M.; Kelson, M.; Lanas, A.; Longley, M.; Phillips, C.J.; et al. Systematic Review and Meta-Analysis of Randomised Trials to Ascertain Fatal Gastrointestinal Bleeding Events Attributable to Preventive Low-Dose Aspirin: No Evidence of Increased Risk. PLoS ONE 2016, 11, e0166166. [CrossRef] [PubMed]

19. Sandler, R.S.; Galanko, J.C.; Murray, S.C.; Helm, J.F.; Woosley, J.T. Aspirin and nonsteroidal anti-inflammatory agents and risk for colorectal adenomas. Gastroenterology 1998, 114, 441–447. [CrossRef]

20. Sandler, R.S.; Halabi, S.; Baron, J.A.; Budinger, S.; Paskett, E.; Keresztes, R.; Petrelli, N.; Pippas, J.M.; Karp, D.D.; Loprinzi, C.L.; et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N. Engl. J. Med. 2003, 348, 883–890. [CrossRef] [PubMed]

21. Cole, B.F.; Logan, R.F.; Halabi, S.; Benamouzig, R.; Sandler, R.S.; Grainge, M.J.; Chaussade, S.; Baron, J.A. Aspirin for the chemoprevention of colorectal adenomas: Meta-analysis of the randomized trials. J. Natl. Cancer Inst. 2009, 101, 256–266. [CrossRef] [PubMed]
22. Burn, J.; Gerdes, A.M.; Macrae, F.; Mecklin, J.P.; Moeslein, G.; Olschwang, S.; Eccle, D.; Evans, D.G.; Maher, E.R.; Bertario, L.; et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: An analysis from the CAP2 randomised controlled trial. *Lancet* 2011, 378, 2081–2087. [CrossRef]

23. Cook, N.R.; Lee, I.M.; Zhang, S.M.; Moorthy, M.V.; Buring, J.E. Alternate-day, low-dose aspirin and cancer risk: Long-term observational follow-up of a randomized trial. *Ann. Intern. Med.* 2013, 159, 77–85. [CrossRef] [PubMed]

24. Din, F.V.; Theodoratou, E.; Farrington, S.M.; Tenesa, A.; Barnetson, R.A.; Cetnarskyj, R.; Stark, L.; Porteous, M.; Campbell, H.; Dunlop, M.G. Effect of aspirin and NSAIDs on risk and survival from colorectal cancer. *Gut* 2010, 59, 1670–1679. [CrossRef] [PubMed]

25. Cuzick, J.; Thorat, M.A.; Bosetti, C.; Brown, P.H.; Burn, J.; Cook, N.R.; Ford, L.G.; Jacobs, E.J.; Jankowski, J.A.; Vecchia, C.L.; et al. Estimates of benefits and harms of prophylactic use of aspirin in the general population. *Ann. Oncol.* 2015, 26, 47–57. [CrossRef] [PubMed]

26. Cao, Y.; Nishihara, R.; Wu, K.; Wang, M.; Ogino, S.; Willett, W.C.; Spigelman, D.; Fuchs, C.S.; Giovannucci, E.L.; Chan, A.T. Population-wide impact of long-term use of aspirin and the risk for cancer. *JAMA Oncol.* 2016, 2, 762–769. [CrossRef] [PubMed]

27. Piazza, G.A.; Rahm, A.K.; Finn, T.S.; Fryer, B.H.; Li, H.; Stoumen, A.L.; Pamukcu, R.; Ahnen, D.J. Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction. *Cancer Res.* 1997, 57, 2452–2459. [PubMed]

28. Alfonso, L.; Ai, G.; Spitale, R.C.; Bhat, G.J. Molecular targets of aspirin and cancer prevention. *Br. J. Cancer* 2014, 111, 61–67. [CrossRef] [PubMed]

29. Thun, M.J.; Jacobs, E.J.; Patrono, C. The role of aspirin in cancer prevention. *Nat. Rev. Clin. Oncol.* 2012, 9, 259–267. [CrossRef] [PubMed]

30. Vane, J.R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. *Nat. New. Biol.* 1971, 231, 232–235. [CrossRef] [PubMed]

31. Pang, L.Y.; Hurst, E.A.; Argyle, D.J. Cyclooxygenase-2: A role in cancer stem cell survival and repopulation of cancer cells during therapy. *Stem Cells Int.* 2016, 2016, 2048731. [CrossRef] [PubMed]

32. Menter, D.G.; DuBois, R.N. Prostaglandins in cancer cell adhesion, migration, and invasion. *Int. J. Cell Biol.* 2012, 2012, 723419. [CrossRef] [PubMed]

33. Williams, C.S.; Mann, M.; DuBois, R.N. The role of cyclooxygenases in inflammation, cancer, and development. *Oncogene* 1999, 18, 7908–7916. [CrossRef] [PubMed]

34. Harris, R.E. Cyclooxygenase-2 (cox-2) and the inflammogenesis of cancer. *Subcell. Biochem.* 2007, 42, 93–126. [PubMed]

35. Chan, A.T.; Ogino, S.; Fuchs, C.S. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. *N. Engl. J. Med.* 2007, 356, 2131–2142. [CrossRef] [PubMed]

36. Chulada, P.C.; Thompson, M.B.; Mahler, J.F.; Doyle, C.M.; Gaul, B.W.; Lee, C.; Tiano, H.F.; Morham, S.G.; Smithies, O.; Langenbach, R. Genetic disruption of PtgS-1, as well as PtgS-2, reduces intestinal tumorigenesis in Min mice. *Cancer Res.* 2000, 60, 4705–4708. [PubMed]

37. Ruegg, C.; Zarić, J.; Stupp, R. Non steroidal anti-inflammatory drugs and COX-2 inhibitors as anti-cancer therapeutics: Hypes, hopes and reality. *Ann. Med.* 2003, 35, 476–487. [CrossRef] [PubMed]

38. Oshima, M.; Dinchuk, J.E.; Kagstrom, S.L.; Oshima, H.; Hancock, B.; Kwong, E.; Trzaskos, J.M.; Evans, J.F.; Taketo, M.M. Suppression of intestinal polyposis in ApcΔ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). *Cell* 1996, 87, 803–809. [CrossRef]

39. Gupta, R.A.; DuBois, R.N. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. *Nat. Rev. Cancer* 2001, 1, 11–21. [CrossRef] [PubMed]

40. Guillem-Llobat, P.; Dovizio, M.; Bruno, A.; Ricciotti, E.; Cufino, V.; Sacco, A.; Grande, R.; Alberti, S.; Arena, V.; Cirillo, M.; et al. Aspirin prevents colorectal cancer metastasis in mice by splitting the crosstalk between platelets and tumor cells. *Oncotarget* 2016, 7, 32462–32477. [CrossRef] [PubMed]

41. Guillem-Llobat, P.; Dovizio, M.; Alberti, S.; Bruno, A.; Patrignani, P. Platelets, cyclooxygenases, and colon cancer. *Semin. Oncol.* 2014, 41, 385–396. [CrossRef] [PubMed]

42. Hanif, R.; Pittas, A.; Feng, Y.; Koutsos, M.I.; Qiao, L.; Staiano-Coico, L.; Shiff, S.I.; Rigas, B. Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. *Biochem. Pharmacol.* 1996, 52, 237–245. [CrossRef]
43. Rigas, B.; Shiff, S.J. Is inhibition of cyclooxygenase required for the chemopreventive effect of NSAIDs in colon cancer? A model reconciling the current contradiction. *Med. Hypotheses* 2000, 54, 210–215. [CrossRef] [PubMed]

44. Zhang, X.; Morham, S.G.; Langenbach, R.; Young, D.A. Malignant transformation and antineoplastic actions of nonsteroidal antiinflammatory drugs (NSAIDs) on cyclooxygenase-null embryo fibroblasts. *J. Exp. Med.* 1999, 190, 451–459. [CrossRef] [PubMed]

45. Mahmoud, N.N.; Boolbol, S.K.; Dannenberg, A.J.; Mestre, J.R.; Bilinski, R.T.; Martucci, C.; Newmark, H.L.; Chadburn, A.; Bertagnolli, M.M. The sulfide metabolite of sulindac prevents tumors and restores enterocyte apoptosis in a murine model of familial adenomatous polyposis. *Carcinogenesis* 1998, 19, 87–91. [CrossRef] [PubMed]

46. Reddy, B.S.; Kawamori, T.; Lubet, R.A.; Steele, V.E.; Kelloff, G.J.; Rao, C.V. Chemopreventive efficacy of sulindac sulfone against colon cancer depends on time of administration during carcinogenic process. *Cancer Res.* 1999, 59, 3387–3391. [PubMed]

47. Tegeder, I.; Pfeilschifter, J.; Geisslinger, G. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. *FASEB J.* 2001, 15, 2057–2072. [CrossRef] [PubMed]

48. Bos, C.L.; Kodach, L.L.; van den Brink, G.R.; Diks, S.H.; van Santen, M.M.; Richel, D.J.; Peppelenbosch, M.P. Hardwick, J.C.H. Effect of aspirin on the Wnt/β-catenin pathway is mediated via protein phosphatase 2A. *Oncogene* 2006, 25, 6447–6456. [CrossRef] [PubMed]

49. Hardie, D.G.; Ross, F.A.; Hawley, S.A. AMP-activated protein kinase: A target for drugs both ancient and modern. *Chem. Biol.* 2012, 19, 1222–1236. [CrossRef] [PubMed]

50. Hawley, S.A.; Fullerton, M.D.; Ross, F.A.; Schertzer, J.D.; Chevtzoff, C.; Walker, K.J.; Peggie, M.W.; Zibrova, D.; Green, K.A.; Mustard, K. The ancient drug salicylate directly activates AMP-activated protein kinase. *Science* 2012, 336, 918–922. [CrossRef] [PubMed]

51. Din, F.V.; Valanciute, A.; Houde, V.P.; Zibrova, D.; Green, K.A.; Sakamoto, K.; Alessi, D.R.; Dunlop, M.G. Aspirin inhibits mTOR signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells. *Gastroenterology* 2012, 142, 1504–1515. [CrossRef] [PubMed]

52. Basseres, D.S.; Baldwin, A.S. Nuclear factor-κB and inhibitor of κB kinase pathways in oncogenic initiation and progression. *Oncogene* 2006, 25, 6817–6830. [CrossRef] [PubMed]

53. DiDonato, J.A.; Mercurio, F.; Karin, M. NF-κB and the link between inflammation and cancer. *Immunol. Rev.* 2012, 246, 379–400. [CrossRef] [PubMed]

54. Perkins, N.D. NF-κB: Tumor promoter or suppressor? *Trends Cell Biol.* 2004, 14, 64–69. [CrossRef] [PubMed]

55. Gilmore, T.D. Introduction to NF-κB: Players, pathways, perspectives. *Oncogene* 2006, 25, 6680–6684. [CrossRef] [PubMed]

56. Hoesel, B.; Schmid, J.A. The complexity of NF-κB signaling in inflammation and cancer. *Mol. Cancer* 2013, 12, 86. [CrossRef] [PubMed]

57. Israel, A. The IKK complex: An integrator of all signals that activate NF-κB? *Trends Cell Biol.* 2000, 10, 129–133. [CrossRef]

58. Vlahopoulos, S.A.; Cen, O.; Hengen, N.; Agan, J.; Moschovi, M.; Critselis, E.; Adamaki, M.; Bacoouliou, F.; Copland, J.A.; Boldogh, I.; et al. Dynamic aberrant NF-κB spurs tumorigenesis: A new model encompassing the microenvironment. *Cytokine Growth Factor Rev.* 2015, 26, 389–403. [CrossRef] [PubMed]

59. Wu, D.; Wu, P.; Zhao, L.; Huang, L.; Zhang, Z.; Zhao, S.; Huang, J. NF-κB Expression and outcomes in solid tumors: A systematic review and meta-analysis. *Medicine* 2015, 94, e1687. [CrossRef] [PubMed]

60. Shaked, H.; Hofseth, L.J.; Chumanevich, A.; Chumanevich, A.A.; Wang, J.; Wang, Y.; Taniguchi, K.; Guma, M.; Shenouda, S.; Clevers, H.; et al. Chronic epithelial NF-κB activation accelerates APC loss and intestinal tumor initiation through iNOS up-regulation. *Proc. Natl. Acad. Sci. USA* 2012, 109, 14007–14012. [CrossRef] [PubMed]

61. Greten, F.R.; Eckmann, L.; Greten, T.F.; Park, J.M.; Li, Z.W.; Egan, L.J.; Kagnoff, M.F.; Karin, M. IKKβ links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. *Cell* 2004, 118, 285–296. [CrossRef] [PubMed]

62. Myant, K.B.; Cammareri, P.; McGhee, E.J.; Ridgway, R.A.; Huels, D.J.; Cordero, J.B.; Schwitalla, S.; Kalna, G.; Ogg, E.-L.; Athineos, O.; et al. ROS production and NF-κB activation triggered by RAC1 facilitate WNT-driven intestinal stem cell proliferation and colorectal cancer initiation. *Cell Stem Cell* 2013, 12, 761–773. [CrossRef] [PubMed]
Biomedicines 2017, 5, 43

63. Kopp, E.; Ghosh, S. Inhibition of NF-κB by sodium salicylate and aspirin. Science 1994, 265, 956–959. [CrossRef] [PubMed]
64. Yin, M.J.; Yamamoto, Y.; Gaynor, R.B. The anti-inflammatory agents aspirin and salicylate inhibit the activity of IκB kinase-β. Nature 1998, 396, 77–80. [PubMed]
65. Stark, L.A.; Dunlop, M.G. Nucleolar sequestration of RelA (p65) regulates NF-κB-driven transcription and apoptosis. Mol. Cell Biol. 2005, 25, 5985–6004. [CrossRef] [PubMed]
66. Takada, Y.; Bhardwaj, A.; Potdar, P.; Aggarwal, B.B. Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-κB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation. Oncogene 2004, 23, 9247–9258. [CrossRef] [PubMed]
67. Yamamoto, Y.; Inatsuka, C.; Lu, H.; Disis, M.L. The invisible arm of immunity in common cancer chemoprevention agents. Cancer Prev. Res. 2013, 6, 764–773. [CrossRef] [PubMed]
68. Liao, D.; Zhong, L.; Duan, T.; Zhang, R.H.; Wang, X.; Wang, G.; Hu, K.; Lv, X.; Kang, T. Aspirin suppresses the ability to suppress NF-κB activation. J. Biol. Chem. 1999, 274, 27307–27314. [CrossRef] [PubMed]
69. Lim, S.Y.; Na, H.K.; Kim, J.W.; Surh, Y.-J.; Song, Y.-S.; Oh, S. Diclofenac attenuates Wnt/β-catenin signaling in colon cancer cells by activation of NF-κB. FEBS Lett. 2005, 579, 4213–4218. [CrossRef] [PubMed]
70. Loveridge, C.J.; Macdonald, A.D.; Thoms, H.C.; Dunlop, M.G.; Stark, L.A. The proapoptotic effects of sulindac, sulindac sulfone and indomethacin are mediated by nucleolar translocation of the RelA(p65) subunit of NF-κB. Oncogene 2008, 27, 2648–2655. [CrossRef] [PubMed]
71. Mladenova, D.; Pangon, L.; Currey, N.; Ng, I.; Musgrove, E.A.; Grey, S.T.; Kohonen-Corish, M.R.J. Sulindac activates NF-κB signaling in colon cancer cells. Cell Commun. Signal. 2013, 11, 73. [CrossRef] [PubMed]
72. Jeong, J.B.; Yang, X.; Clark, R.; Choi, J.; Baek, S.J.; Lee, S.H. A mechanistic study of the proapoptotic effect of tolfenamic acid: Involvement of NF-κB activation. Carcinogenesis 2013, 34, 2350–2360. [CrossRef] [PubMed]
73. Park, I.S.; Jo, J.R.; Hong, H.; Nam, K.Y.; Kim, J.B.; Hwang, S.H.; Choi, M.S.; Ryu, N.H.; Jang, H.J.; Lee, S.H.; et al. Aspirin induces apoptosis in YD-8 human oral squamous carcinoma cells through activation of caspases, down-regulation of Mcl-1, and inactivation of ERK1/2 and AKT. Toxicol. In Vitro 2010, 24, 713–720. [CrossRef] [PubMed]
74. Greenspan, E.J.; Madigan, J.P.; Boardman, L.A.; Rosenberg, D.W. Ibuprofen inhibits activation of nuclear β-catenin in human colon adenomas and induces the phosphorylation of GSK-3β. Cancer Prev. Res. 2011, 4, 161–171. [CrossRef] [PubMed]
75. Stark, L.A.; Reid, K.; Sansom, O.J.; Din, F.V.; Guichard, S.; Mayer, I.; Jodrell, D.I.; Clarke, A.R.; Dunlop, M.G. Aspirin activates the NF-κB signalling pathway and induces apoptosis in intestinal neoplasia in two in vivo models of human colorectal cancer. Carcinogenesis 2007, 28, 968–976. [CrossRef] [PubMed]
76. Chen, J.; Lobb, I.; Pierre, M.; Sonia, M.N.; James, S.; Kathrin, K.; Kathrin, K.; Kathrin, K.; Oakley, F.; Stark, L.A. Disruption of the P53 complex links inhibition of CDK4 activity to activation of the NF-κB pathway. Available online: http://biomark.org/content/biorxiv/early/2017/01/13/100255.full.pdf (accessed on 13 January 2017).
77. Grivennikov, S.I.; Greten, F.R.; Karin, M. Immunity, inflammation, and cancer. Cell 2010, 140, 883–899. [CrossRef] [PubMed]
78. Marzbani, E.; Inatsuka, C.; Lu, H.; Disis, M.L. The invisible arm of immunity in common cancer chemoprevention agents. Cancer Prev. Res. 2013, 6, 764–773. [CrossRef] [PubMed]
79. Cao, Y.; Nishihara, R.; Qian, Z.R.; Song, M.; Mima, K.; Inamura, K.; Nowak, J.A.; Drew, D.A.; Lochhead, P.; Nosho, K.; et al. Regular aspirin use associates with lower risk of colorectal cancers with low numbers of tumor-infiltrating lymphocytes. Gastroenterology 2016, 151, 879–892. [CrossRef] [PubMed]
80. Boulon, S.; Westman, B.J.; Hutten, S.; Boisvert, F.M.; Lamond, A.I. The nucleolus under stress. Mol. Cell 2010, 40, 216–227. [CrossRef] [PubMed]
81. Grummt, I. The nucleolus-guardian of cellular homeostasis and genome integrity. Chromosoma 2013, 122, 487–497. [CrossRef] [PubMed]
83. James, A.; Wang, Y.; Raje, H.; Rosby, R.; DiMario, P. Nucleolar stress with and without p53. *Nucleus* **2014**, *5*, 402–426. [CrossRef] [PubMed]
84. Russo, A.; Russo, G. Ribosomal Proteins Control or Bypass p53 during Nucleolar Stress. *Int. J. Mol. Sci.* **2017**, *18*, 140. [CrossRef] [PubMed]
85. Thul, P.J.; Akesson, L.; Wiking, M.; Mahdessian, D.; Geladaki, A.; Ait, B.H.; Alm, T.; Asplund, A.; Björk, L.; Breckels, L.M.; et al. A subcellular map of the human proteome. *Science* **2017**, *356*. [CrossRef] [PubMed]
86. Andersen, J.S.; Lam, Y.W.; Leung, A.K.; Ong, S.E.; Lyon, C.E.; Lamond, A.I.; Mann, M. Nucleolar proteome localization and changes induced by DNA damage. *Mol. Cell. Proteom.* **2010**, *9*, 457–470. [CrossRef] [PubMed]
87. Boisvert, F.M.; Lam, Y.W.; Lamont, D.; Lamond, A.I. A quantitative proteomics analysis of subcellular localization of phosphorylated eIF2α subunit of eukaryotic initiation factor 2 is required for activation of NF-κB. *Mol. Cell. Biol.* **2003**, *23*, 5651–5663. [CrossRef] [PubMed]
88. Coccia, M.; Rossi, A.; Riccio, A.; Trotta, E.; Santoro, M.G. Human NF-κB repressing factor acts as a stress-regulated switch for ribosomal RNA processing and nucleolar homeostasis surveillance. *Proc. Natl. Acad. Sci. USA* **2017**, *114*, 1045–1050. [CrossRef] [PubMed]
89. Rubbi, C.P.; Milner, J. Non-activated p53 co-localizes with sites of transcription within both the nucleoplasm and the nucleolus. *Oncogene* **2000**, *19*, 85–96. [CrossRef] [PubMed]
90. Audas, T.E.; Jacob, M.D.; Lee, S. Immobilization of proteins in the nucleolus by ribosomal intergenic spacer noncoding RNA. *Mol. Cell* **2012**, *45*, 147–157. [CrossRef] [PubMed]
91. Latonen, L. Nucleolar aggresomes as counterparts of cytoplasmic aggresomes in proteotoxic stress. *Bioessays* **2011**, *33*, 386–395. [CrossRef] [PubMed]
92. Latonen, L.; Moore, H.M.; Bai, B.; Jaamaa, S.; Laiho, M. Proteasome inhibitors induce nucleolar aggregation of proteasome target proteins and polyadenylated RNA by altering ubiquitin availability. *Oncogene* **2011**, *30*, 790–805. [CrossRef] [PubMed]
93. Ehm, P.; Nalaskowski, M.M.; Wundenberg, T.; Jucker, M. The tumor suppressor SHIP1 colocalizes in nucleolar cavities with p53 and components of PML nuclear bodies. *Nucleus* **2015**, *6*, 154–164. [CrossRef] [PubMed]
94. Rocha, S.; Campbell, K.J.; Perkins, N.D. p53- and Mdm2-independent repression of NF-κB transactivation by the ARF tumor suppressor. *Mol. Cell* **2003**, *12*, 15–25. [CrossRef]
95. Sweet, T.; Khalili, K.; Sawaya, B.E.; Amini, S. Identification of a novel protein from glial cells based on its ability to interact with NF-κB subunits. *J. Cell. Biochem.* **2003**, *90*, 884–891. [CrossRef] [PubMed]
96. Dhar, S.K.; Lynn, B.C.; Daosukho, C.; St Clair, D.K. Identification of nucleophosmin as an NF-κB co-activator for the induction of the human SOD2 gene. *J. Biol. Chem.* **2004** . [CrossRef] [PubMed]
97. Birbach, A.; Bailey, S.T.; Ghosh, S.; Schmid, J.A. Cytosolic, nucleolar and nucleolar localization signals determine subcellular distribution and activity of the NF-κB inducing kinase NIK. *J. Cell Sci.* **2004**, *117*, 3615–3624. [CrossRef] [PubMed]
98. Niedick, I.; Froese, N.; Oumard, A.; Mueller, P.P.; Nourbakhsh, M.; Hauser, H.; Köster, M. Nucleolar localization and mobility analysis of the NF-κB repressing factor NRF. *J. Cell Sci.* **2004**, *117*, 3447–3458. [CrossRef] [PubMed]
99. Bierhoff, H.; Dandri, M.; Michels, A.A.; Grummt, I. Phosphorylation by casein kinase 2 facilitates rRNA gene transcription by promoting dissociation of TIF-IA from elongating RNA polymerase I. *Mol. Cell. Biol.* **2008**, *28*, 4989–4998. [CrossRef] [PubMed]
100. Kato, T., Jr.; Delhase, M.; Hoffmann, A.; Karin, M. CK2 is a C-terminal IκB kinase responsible for NF-κB activation during the UV response. *Mol. Cell* **2003**, *12*, 829–839. [CrossRef]
101. Jiang, H.Y.; Wek, S.A.; McGrath, B.C.; Scheuner, D.; Kaufman, R.J.; Cavener, D.R.; Wek, R.C. Phosphorylation of the α subunit of eukaryotic initiation factor 2 is required for activation of NF-κB in response to diverse cellular stresses. *Mol. Cell. Biol.* **2003**, *23*, 5651–5663. [CrossRef] [PubMed]
102. Goldstein, E.N.; Owen, C.R.; White, B.C.; Rafols, J.A. Ultrastructural localization of phosphorylated eIF2α [eIF2α(P)] in rat dorsal hippocampus during reperfusion. *Acta Neuropathol.* **1999**, *98*, 493–505. [CrossRef] [PubMed]
103. Thoms, H.C.; Loveridge, C.J.; Simpson, J.; Clipson, A.; Reinhardt, K.; Dunlop, M.G.; Stark, L.A. Nucleolar targeting of RelA(p65) is regulated by COMMD1-dependent ubiquitination. *Cancer Res.* **2010**, *70*, 139–149. [CrossRef] [PubMed]
104. Parrondo, R.; de las, P.A.; Reiner, T.; Rai, P.; Perez-Stable, C. NF-κB activation enhances cell death by antimitotic drugs in human prostate cancer cells. Mol. Cancer 2010, 9, 182. [CrossRef] [PubMed]

105. Sniderhan, L.F.; Garcia-Bates, T.M.; Burgart, M.; Bernstein, S.H.; Phipps, R.P.; Maggirwar, S.B. Neurotrophin signaling through tropomyosin receptor kinases contributes to survival and proliferation of non-Hodgkin lymphoma. Exp. Hematol. 2009, 37, 1295–1309. [CrossRef] [PubMed]

106. Lee, D.H.; Forscher, C.; Di, V.D.; Koefler, H.P. Induction of p53-independent apoptosis by ectopic expression of HOXA5 in human liposarcomas. Sci. Rep. 2015, 5, 12580. [CrossRef] [PubMed]

107. Thoms, H.C.; Dunlop, M.G.; Stark, L.A. p38-mediated inactivation of cyclin D1/cyclin-dependent kinase 4 stimulates nucleolar translocation of RelA and apoptosis in colorectal cancer cells. Cancer Res. 2007, 67, 1660–1669. [CrossRef] [PubMed]

108. Dadsetan, S.; Balzano, T.; Forteza, J.; Cabrera-Pastor, A.; Taoro-Gonzalez, L.; Hernandez-Rabaza, V.; Gil-Perotin, S.; Cubas-Nunez, L.; Garcia-Verdugo, J.M.; Agusti, A.; et al. Reducing peripheral inflammation with infliximab reduces neuroinflammation and improves cognition in rats with hepatic encephalopathy. Front. Mol. Neurosci. 2016, 9, 106. [CrossRef] [PubMed]

109. Khandelwal, N.; Simpson, J.; Taylor, G.; Rafique, S.; Whitehouse, A.; Hiscox, J.; Stark, L.A. Nucleolar NF-κB/RelA mediates apoptosis by causing cytoplasmic relocalization of nucleophosmin. Cell Death Differ. 2011, 18, 1899–1903. [CrossRef] [PubMed]

110. Kerr, L.E.; Birse-Archbold, J.L.; Short, D.M.; McGregor, A.L.; Heron, I.; Macdonald, D.C.; Thompson, J.; Carlson, G.J.; Kelly, J.S.; McCulloch, J.; et al. Nucleophosmin is a novel Bax chaperone that regulates apoptotic cell death. Oncogene 2007, 26, 2554–2562. [CrossRef] [PubMed]

111. Wang, Z.; Gall, J.M.; Bonegio, R.; Havasi, A.; Illanes, K.; Schwartz, J.H.; Borkan, S.C. Nucleophosmin, a critical Bax cofactor in ischemia-induced cell death. Mol. Cell. Biol. 2013, 33, 1916–1924. [CrossRef] [PubMed]

112. Zhang, L.; Yu, J.; Park, B.H.; Kinzler, K.W.; Vogelstein, B. Role of BAX in the apoptotic response to anticancer agents. Science 2000, 290, 989–992. [CrossRef] [PubMed]

113. Tatham, M.H.; Cole, C.; Scullion, P.; Wilkie, R.; Westwood, N.J.; Stark, L.A.; Hey, R.T. A proteomic approach to analyze the aspirin-mediated lysine acetylome. Mol. Cell. Proteom. 2017, 16, 310–326. [CrossRef] [PubMed]

114. Wang, J.; Zhang, C.J.; Zhang, J.; He, Y.; Lee, Y.M.; Chen, S.; Lim, T.K.; Ng, S.; Shen, H.M.; Lin, Q. Mapping sites of aspirin-induced acetylations in live cells by quantitative acid-cleavable activity-based protein profiling (QA-ABPP). Sci. Rep. 2015, 5, 7896. [CrossRef] [PubMed]

115. Chan, T.A.; Morin, P.J.; Vogelstein, B.; Kinzler, K.W. Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. Proc. Natl. Acad. Sci. USA 1998, 95, 681–686. [CrossRef] [PubMed]

116. Charruyer, A.; Grazide, S.; Bezemkes, C.; Muller, S.; Laurent, G.; Jaffrezou, J.P. UV-C light induces raft-associated acid sphingomyelinase and JNK activation and translocation independently on a nuclear signal. J. Biol. Chem. 2005, 280, 19196–19204. [CrossRef] [PubMed]